UY26454A1 - Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida - Google Patents

Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida

Info

Publication number
UY26454A1
UY26454A1 UY26454A UY26454A UY26454A1 UY 26454 A1 UY26454 A1 UY 26454A1 UY 26454 A UY26454 A UY 26454A UY 26454 A UY26454 A UY 26454A UY 26454 A1 UY26454 A1 UY 26454A1
Authority
UY
Uruguay
Prior art keywords
tetrahydrokinoline
carboxamine
substituted crystal
crystals
substituted
Prior art date
Application number
UY26454A
Other languages
English (en)
Spanish (es)
Inventor
Lyle Robinson Brostrom
Douglas John Meldrum Allen
Troy Anthony Appleton
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY26454A1 publication Critical patent/UY26454A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UY26454A 1999-11-30 2000-11-28 Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida UY26454A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
UY26454A1 true UY26454A1 (es) 2001-07-31

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26454A UY26454A1 (es) 1999-11-30 2000-11-28 Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida

Country Status (28)

Country Link
EP (1) EP1246804A1 (fr)
JP (1) JP2003515592A (fr)
KR (1) KR20020058057A (fr)
CN (1) CN1402711A (fr)
AP (1) AP2002002531A0 (fr)
AU (1) AU1048801A (fr)
BG (1) BG106854A (fr)
BR (1) BR0015836A (fr)
CA (1) CA2392979A1 (fr)
CO (1) CO5271716A1 (fr)
EA (1) EA200200510A1 (fr)
EC (1) ECSP003792A (fr)
EE (1) EE200200277A (fr)
GT (1) GT200000199A (fr)
HU (1) HUP0203521A2 (fr)
IL (1) IL149097A0 (fr)
IS (1) IS6338A (fr)
MA (1) MA26845A1 (fr)
MX (1) MXPA02005354A (fr)
NO (1) NO20022558L (fr)
OA (1) OA12099A (fr)
PA (1) PA8506301A1 (fr)
PE (1) PE20010904A1 (fr)
PL (1) PL355892A1 (fr)
TN (1) TNSN00231A1 (fr)
TR (1) TR200201446T2 (fr)
UY (1) UY26454A1 (fr)
WO (1) WO2001040190A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
BR0210505A (pt) 2001-06-21 2004-05-18 Pfizer Prod Inc Formulações auto-emulsionantes de inibidores da proteìna de transferência de ésteres de colesterilo
GT200200170A (es) 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
EP1920766B1 (fr) * 2002-02-01 2017-08-23 Bend Research, Inc Compositions pharmaceutiques de dispersions amorphes de médicaments et matériaux formant des microphases lipophiles
BR0307344A (pt) 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
PT1469833T (pt) * 2002-02-01 2021-07-13 Bend Res Inc Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado
DE60311821T2 (de) 2002-08-30 2007-10-31 Japan Tobacco Inc. Dibenzylaminverbindung und deren medizinische verwendung
BR0315041A (pt) 2002-10-04 2005-08-16 Millennium Pharm Inc Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
WO2004085401A1 (fr) * 2003-03-28 2004-10-07 Pfizer Products Inc. Derives de 1,2,3,4-tetrahydro- et 1,2 dihydro-quinoleine et 1,2,3,4-tetrahydro-quinoxaline 1,2,4-substitues, utiles comme inhibiteurs de cetp pour le traitement de l'atherosclerose et de l'obesite
WO2005011635A2 (fr) 2003-08-04 2005-02-10 Pfizer Products Inc. Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles
KR20060085675A (ko) 2003-10-08 2006-07-27 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
AU2005233160B2 (en) * 2004-04-13 2011-06-02 Merck Sharp & Dohme Corp. CETP inhibitors
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
WO2006033001A1 (fr) * 2004-09-23 2006-03-30 Pfizer Products Inc. Composes de quinoline
ZA200707498B (en) 2005-02-24 2008-11-26 Millennium Pharm Inc PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (fr) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (fr) 2008-12-16 2011-10-26 Schering Corporation Dérivés de pyridopyrimidine et leurs procédés d'utilisation
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
ES2825675T3 (es) 2014-07-30 2021-05-17 Hoffmann La Roche Marcadores genéticos para predecir la reactividad al tratamiento con un agente que aumenta las HDL o que imita las HDL

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (fr) * 1997-02-03 1998-08-06 American Home Products Corporation Derives de l'-1-acyl-1,2-dihydroquinoline substituee en 2 augmentant la concentration en cholesterol hdl
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
MA26845A1 (fr) 2004-12-20
NO20022558D0 (no) 2002-05-29
TNSN00231A1 (fr) 2002-05-30
KR20020058057A (ko) 2002-07-12
BR0015836A (pt) 2002-08-06
GT200000199A (es) 2002-05-23
JP2003515592A (ja) 2003-05-07
PE20010904A1 (es) 2001-09-10
EA200200510A1 (ru) 2002-10-31
EE200200277A (et) 2003-10-15
IS6338A (is) 2002-04-12
PA8506301A1 (es) 2002-08-26
AP2002002531A0 (en) 2002-06-30
EP1246804A1 (fr) 2002-10-09
CN1402711A (zh) 2003-03-12
ECSP003792A (es) 2002-04-23
CA2392979A1 (fr) 2001-06-07
WO2001040190A1 (fr) 2001-06-07
AU1048801A (en) 2001-06-12
TR200201446T2 (tr) 2002-11-21
CO5271716A1 (es) 2003-04-30
NO20022558L (no) 2002-05-29
PL355892A1 (en) 2004-05-31
OA12099A (en) 2006-05-04
MXPA02005354A (es) 2002-12-11
HUP0203521A2 (hu) 2003-02-28
BG106854A (bg) 2002-12-29
IL149097A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
UY26454A1 (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida
ES2090713T3 (es) Sales organicas de n,n'-diacetil-cistina.
UY24555A1 (es) Nuevos compuestos
AR011069A1 (es) Compuestos amidino, proceso para su preparacion, compuestos intermediarios, formulaciones farmaceuticas que los comprenden, y su uso en la fabricacion de un medicamento como inhibidor de la oxido nitrico sintasa inducible.
ES2053451T3 (es) Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
DK1007520T3 (da) 2-aminopyridiner som indeholder sammensluttede ringsubstituenter som NOS inhibitorer
AR023777A1 (es) Nuevos compuestos
ES2133543T3 (es) Derivados de pirrolidina y oxazolidina, su preparacion y su uso como inhibidores de la agregacion de trombocitos.
AR021355A1 (es) Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
NO934628L (no) Retrovirus-protease-inhibitorer
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
AR028443A1 (es) Nuevos compuestos derivados de piperazina y piperidina, metodo para su preparacion, composiciones farmaceuticas que los contienen y preparacion de las mismas y uso de dichos compuestos
DK0391171T3 (da) Anvendelse af di-styryl-phenyl-triglycolether som krystallisationsinhibitor
HN2001000235A (es) Derivados puentes de piperazina
AR046131A1 (es) Formas cristalinas de {2-[1-(3,5- bistrifluorurometilbencil)-5- piridin-4-il-1h-[1,2,3]triazol- 4-il]piridin- 3-il}-(2-clorofenil)metanona
DK1051177T3 (da) Steroide 3-O-Sulfamatderivater som inhibitorer af östronsulfatase
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ES2186989T3 (es) Cristales de maltitol de formas especificas, compuestos cristalinos que los contienen y procedimientos para su preparacion.
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
PA8495001A1 (es) Nuevas formas cristalinas de un antibiotico macrolido.
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
MX9200874A (es) Compuestos de una composicion especifica, un procedimiento para su produccion y su uso.
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120529